Next steps for the first national donor image sharing hub
Learnings from the pilot will help inform a national rollout

Learnings from the pilot will help inform a national rollout

Hibernicor intends to develop a master plan for a multi-story multipurpose building designed with the primary objective of medical device manufacturing in a urban area with access to an international airport and multiple commuting options. The building shall have a total floor area not to exceed 100,000 square feet with an
Using the new Center Acceptance and Refusal Evaluation (CARE) tool, transplant centers can see all of

INSIGHTS
Companies at the forefront of organ perfusion technology
“The transplant administrator, at the end of the day, is really the heart

Insights: FEATURE
A look at the rapidly evolving technology that could make more organs available than ever before.
With the growing shortage of organ donors, marginal donor organs are increasingly accepted, which may partially explain the continued increase in donor age. The potential interactions between donor-recipient (D/R) age difference and outcomes after heart transplantation (HT) are not well known, and organ allocation systems do not routinely consider D/R age matching. We thus aimed
Our hypothesis is that by improving access to advanced heart failure specialists (AHFS) through partnered outreach clinics, we can increase the number of patients benefitted by advanced heart failure (AHF) therapies delivered at our center. This partnered network approach can potentially overcome distance barriers, optimize referral timing, and expedite access to AHFS from the regional
Psychosocial assessment is a key component of heart transplantation (HT) evaluation. Criteria such as patient compliance to medical therapy, level of social support, and history of substance abuse are important considerations when assessing appropriateness for listing. The aim of this study was to characterize the patients who do not satisfy listing criteria due to psychosocial
Despite the controversial effect of elevated heart rate on progression of cardiac allograft vasculopathy (CAV), heart-rate-slowing agents are frequently prescribed with the assumption that higher heart rate predicts worse outcomes in cardiovascular disease.